Gencurix Inc.

KOSDAQ 229000.KQ

Gencurix Inc. Return on Equity (ROE) for the year ending December 31, 2023: -139.81%

Gencurix Inc. Return on Equity (ROE) is -139.81% for the year ending December 31, 2023, a 63.20% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Gencurix Inc. Return on Equity (ROE) for the year ending December 31, 2022 was -379.86%, a -239.55% change year over year.
  • Gencurix Inc. Return on Equity (ROE) for the year ending December 31, 2021 was -111.87%, a -280.36% change year over year.
  • Gencurix Inc. Return on Equity (ROE) for the year ending December 31, 2020 was 62.03%, a 101.05% change year over year.
  • Gencurix Inc. Return on Equity (ROE) for the year ending December 31, 2019 was -5,904.25%.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
KOSDAQ: 229000.KQ

Gencurix Inc.

CEO Sung-Rai Cho
IPO Date April 5, 2017
Location South Korea
Headquarters Hanhwa Bizmetro
Employees 69
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.

StockViz Staff

January 15, 2025

Any question? Send us an email